AQR Capital Management LLC Makes New Investment in BioAtla, Inc. (NASDAQ:BCAB)

AQR Capital Management LLC acquired a new stake in BioAtla, Inc. (NASDAQ:BCAB - Free Report) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 636,136 shares of the company's stock, valued at approximately $872,000. AQR Capital Management LLC owned about 1.32% of BioAtla at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the stock. Price T Rowe Associates Inc. MD bought a new position in BioAtla during the 1st quarter worth approximately $45,000. Acadian Asset Management LLC grew its holdings in shares of BioAtla by 57.6% in the 1st quarter. Acadian Asset Management LLC now owns 155,188 shares of the company's stock valued at $532,000 after buying an additional 56,748 shares during the period. Virtu Financial LLC bought a new stake in shares of BioAtla in the 1st quarter valued at $103,000. Vanguard Group Inc. raised its stake in BioAtla by 0.8% during the 1st quarter. Vanguard Group Inc. now owns 2,099,037 shares of the company's stock worth $7,221,000 after buying an additional 17,667 shares during the period. Finally, PVG Asset Management Corp bought a new position in BioAtla during the fourth quarter worth about $161,000. Institutional investors and hedge funds own 77.23% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, JMP Securities restated a "market outperform" rating and issued a $5.00 price target on shares of BioAtla in a report on Monday, September 16th.

BioAtla Price Performance

BCAB stock traded up $0.14 during mid-day trading on Friday, reaching $2.07. The company had a trading volume of 828,753 shares, compared to its average volume of 835,896. The company has a market capitalization of $100.06 million, a price-to-earnings ratio of -0.95 and a beta of 1.06. BioAtla, Inc. has a 52 week low of $1.14 and a 52 week high of $4.02. The stock has a 50 day simple moving average of $1.78 and a two-hundred day simple moving average of $2.04.

BioAtla (NASDAQ:BCAB - Get Free Report) last issued its earnings results on Thursday, August 8th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.45) by $0.01. During the same quarter in the prior year, the firm earned ($0.75) earnings per share. On average, equities analysts predict that BioAtla, Inc. will post -1.52 EPS for the current year.

BioAtla Company Profile

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.